Earnings Call · Q4 FY2023·2024-03-07

Q4 23EPS -28.70%·Rev n/aQ3 23EPS +20.83%·Rev n/aQ2 23EPS +11.58%·Rev n/aQ1 23EPS +30.47%·Rev n/a⚠ consensus missing

Phathom Pharmaceuticals, Inc. PHAT

Eric Sciorilli — Head of Investor Relations

Terrie Curran — President and CEO

Martin Gilligan — Chief Commercial Officer

Molly Henderson — Chief Financial Officer

−6.6%1d on move date−7.6% vs SPY3d−15.1%5d−17.8%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more PHAT calls or request research access.

More PHAT calls Browse calls Request research access